Fairvalue-Calculator Fairvalue-Calculator
EN DE

PT Indo Acidatama Tbk (SRSN) Fair Value & Analysis

Basic Materials · ID · Market cap 355B IDR

Price73.00 IDR
Fair Value218.44 IDR
Upside+199.2%
Quality95/100
Evidence: High Range 163.83 IDR – 273.05 IDR

Fair value as of: Jun 25, 2026

Analysis

PT Indo Acidatama Tbk (SRSN) currently trades at 73.00 IDR, while our model-based Fair Value estimate is 218.44 IDR — implying the stock looks roughly 199.2% undervalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

PT Indo Acidatama Tbk operates as an agro-chemical company in Indonesia. The company offers ethanol and acetic acid products; and agro products, such as liquid biofertilizer, organic fertilizer, decomposer, liquid organic fertilizer, liquid organic soil conditioner, and bio-organic fertilizer, as well as farm, fishery, and other products. It also exports its products. The company was formerly known as PT Sarasa Nugraha Tbk and changed its name to PT Indo Acidatama Tbk in May 2006. PT Indo Acidatama Tbk was founded in 1982 and is headquartered in Jakarta, Indonesia.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is PT Indo Acidatama Tbk (SRSN) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 218.44 IDR versus a price of 73.00 IDR — about +199% (undervalued). Model-based estimate, not financial advice.
What is the fair value of SRSN?
Our 21-model fair value for PT Indo Acidatama Tbk is 218.44 IDR (as of Jun 25, 2026), built from audited fundamentals. The current price is 73.00 IDR.
What is the quality score of SRSN?
PT Indo Acidatama Tbk has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.